Harpoon Therapeutics shares are trading lower after AbbVie decided not to exercise the exclusive license option for the HPN217 program.
Portfolio Pulse from Benzinga Newsdesk
Harpoon Therapeutics' stock is trading lower after AbbVie decided not to exercise the exclusive license option for the HPN217 program.
September 14, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harpoon Therapeutics' shares are expected to trade lower due to AbbVie's decision not to exercise the exclusive license option for the HPN217 program.
AbbVie's decision not to exercise the exclusive license option for the HPN217 program directly impacts Harpoon Therapeutics. This decision could be perceived negatively by the market, leading to a potential decrease in Harpoon's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100